Adcendo appoints new management

Thursday 13 January 2022
Adcendo ApS
Appointee name
Carmel Lynch and Pernille Høyrup Hemmingsen


Denmark-based Adcendo ApS has recruited two new members to its management team to help direct development of its pipeline of antibody-drug conjugates (ADCs). Carmel Lynch joins as chief development officer and Pernille Høyrup Hemmingsen as chief technology officer. Dr Lynch is a pharmacologist who led the nonclinical and clinical pharmacology work at Seattle Genetics for brentuximab vedotin, approved in the US in 2011 for lymphoma. She received her PhD at University College Dublin, Ireland.

Dr Hemmingsen was most recently head of global product development and supply at Savara ApS, a Danish company developing drugs for respiratory diseases. She holds a PhD in biophysical chemistry from the Technical University of Denmark.

Adcendo announced the appointments on 1 December 2021.

Copyright 2022 Evernow Publishing Ltd